🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Over 1200 #amyloidosis patients and caregivers participated in our 2022 Community Survey during April and May of last year. See what they had to share about their #AL #ATTR #AA and other amyloidosis journeys: arci.org/arc-2022-commu…

#Acoramidis for #amyloidosis: From bench to bedside with Dr. Daniel Judge shorturl.at/kxBGU #AHA23

Wishing you and yours a healthy and happy holiday season! 🫀👏🏻✨☺️

Proud to be a part of this study Sylvester Comprehensive Cancer Center - we need some competition in the TTR stabilizer space… more options for our ATTR patients! Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | NEJM nejm.org/doi/full/10.10…

ATTRibute-CM paper is out in NEJM Acoramidis vs placebo in #ATTR cardiomyopathy nejm.org/doi/full/10.10… #CatdioTwitter

We are thrilled to read this hot off-the-press paper and congratulate the PIs and #DanJudge for leading both phase 2 & 3 studies at our program MUSC Health. A positive impact for the medical community and most importantly, for patients with amyloidosis. Thank you all! 🌟🫀🎉

Grateful for the teachings of #MLK - his work will continue on as we proceed in life ✨ #MLKDay #Humanity

Enroll in the In Our DNA SC community health research project & embrace a healthier you in 2024! Participants will receive results for their genetic risks for certain cancers & heart disease. Your health matters - make it a priority by enrolling today at inourdnasc.org!

The rarest day of the year is finally here: it's #RareDiseaseDay! 🦓 Tag us in your posts today as you #ShowYourStripes and check out our website to add to our "Faces of Rare" dedication wall, download social media graphics, and more: bit.ly/2BrULms🦓

"At NIH, we are committed to taking on the challenges of #RareDiseases." - NIH Director. There's been a lot of progress and we're starting to crack some of the toughest challenges, but "we're not done. We have so much more to do."

AL #amyloidosis is a serious disease. However, many patients benefit from current therapies, with their lives improved and prolonged, often for many years. Learn more about the current treatment options for the disease: arci.org/resource/treat…

So exciting to see these therapies on the pipeline!! Especially as more and more patient are diagnosed, should we start therapy early? #THT2024 ⁦MUSC Amyloidosis Center⁩

⏳early registration for #ISA2024 ending soon. Virtual & in person, state of the art #amyloidosis Amyloidosis_ARC Amyloidosis Support Mayo Amyloid BU Amyloidosis Center MUSC Amyloidosis Center Mayo Clinic CV Michelle Kittleson MD PhD Brett Sperry, MD Ahmad Masri Mazen Hanna cveducation.mayo.edu/store/internat…

Disparity in dx of ATTR #amyloidosis in African Americans (V122/142I) assoc w/ poor outcomes Kevin Alexander Saurabh Malhotra Justin L. Grodin & great talk by Nitasha Sarswat on how this impacts diversity in clinical trials: need to⬇️barriers to test/treat/trials - go to the pts! #ISA2024

Forward thinking session to end #ISA24 on clinical trial endpoints in Amyloidosis. Phenomenal conference learning from diverse amyloid specialists from around the world The International Society Of Amyloidosis